Regulatory T Cells and Autoimmune Diseases addresses recent findings concerning the role of Tregs in the pathogenesis of autoimmune diseases as well as their therapeutic applications. In particular, this book deals with various Treg-based mechanisms that can lead to autoimmune disease and covers different aspects linking Tregs with autoimmune mechanisms involved in disease development by discussing animal models and human studies.
This book specifically focuses on Treg-based therapeutics and their targets to manage all known autoimmune rheumatic, central nervous system, bowel, liver, thyroid, kidney, myopathic, skin, blood and blood vessel, and eye diseases and aims to provide a must-have reference for designing therapeutic strategies to treat these autoimmune diseases. Additionally, this book covers vaccine-induced effects on the functioning of Tregs and development of CAR Treg therapy for autoimmune diseases and concludes with current challenges and future prospects of Treg-based therapeutics. This book is carefully designed to meet the requirements of both basic and advanced researchers in the area and provide new dimensions and insight into regulatory T cells’ role in autoimmune disease pathogenesis and therapy.
Author Biography:
Mitesh Kumar Dwivedi, PhD, is an assistant professor of microbiology at the C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University. He has published 63 research papers and 46 book chapters, edited 8 books, and serves as an editorial board member and reviewer of many international journals. He has an h-index of 25 with 2261 citations for his research papers. His research interests include investigation of immunogenetic, autoimmune, and therapeutic aspects of vitiligo, rheumatoid arthritis, sickle cell disease, and the role of probiotics in amelioration of autoimmune diseases. He is a recipient of numerous honors: DST-SERB Core Research Grant (2022), SERB-SIRE International Research Fellowship (2022), Best Researcher Award (2020), INSA Visiting Scientist Award (2019), DST-SERB Early Career Research Award (2018), Young Scientist Awards (2011, 2013, and 2018), and all India rank “32 in CSIR-NET national examination (2011; Life Sciences). He has successfully completed six research projects as principal investigator from national funding agencies: SERB-DST, GUJCOST, UTU, and Neo Sciences & Research Solutions Pvt. Ltd. and guided students for their doctoral and master degrees.
DeLisa Fairweather, PhD, is a professor of medicine and immunology and director of translational research in the Department of Cardiovascular Medicine at Mayo Clinic in Jacksonville, Florida, studying sex/gender differences in cardiovascular and autoimmune diseases, including myocarditis. Her research has been continuously funded by the National Institutes of Health (NIH), the American Heart Association (AHA), BARDA, and others. She serves on NIH, the Board of the Atwal Clinic and Mayo Clinic Mitochondrial Research Center, and formerly on the Board of the Myocarditis Foundation. She was a leader of the US FDA Mayo-led Expanded Access Program during the COVID-19 pandemic. She has served on the National Academies of Sciences, Engineering, and Medicine (NASEM) committee making recommendations to NIH and Congress on the autoimmune disease portfolio of NIH and on the NASEM committee to examine side effects of COVID-19 vaccines. She is a member of the Scientific Advisory Board for the Autoimmune Registry as well as the Organization for the Study of Sex Differences (OSSD).
